1 / 25

Amine Autacoids Histamine & 5-Hydroxytryptamine

Amine Autacoids Histamine & 5-Hydroxytryptamine. Dr Mahmoud Khattab. Histamine Source, Storage & Release. Histamine is an amine, derived from the amino acid histidine by L-histidine decarboxylase Storage: In mast cells mainly in lungs, skin & GIT mucosa, as an inactive complex with heparin

oliana
Download Presentation

Amine Autacoids Histamine & 5-Hydroxytryptamine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Amine AutacoidsHistamine & 5-Hydroxytryptamine Dr Mahmoud Khattab

  2. HistamineSource, Storage & Release • Histamine is an amine, derived from the amino acid histidine by L-histidine decarboxylase • Storage: • In mast cells mainly in lungs, skin & GIT mucosa, as an inactive complex with heparin • In platelets & basophilic leukocytes • In CNS • Enterochromaffin-like (ECL) cells of the stomach • Histamine inactivation is via N-methylation or oxidative deamination into Me-histamine/imidazole acetic acid

  3. Histamine Release • Immunologic Release (Cell destruction): mast cell & basophils degranulate when exposed to the appropriate antigen (bacterial toxins, sing venom, cold, injury) • Chemical Release: by drugs like morphine, vancomycin & curare, X-ray contrast media, foreign proteins • Dissolution of cytoplasmic granules by radiation and surfactants

  4. Histamine Receptors & Mechanism of Action • Histamine has four histamine H1, H2, H3, & H4 G-protein coupled receptors • Vasodilatation is via endothelial H1 receptors& smooth muscle H2 receptors • H1 stimulation → Increased intracellular Ca2+ → Activation of PLA2 → PGI2 & NO production → Diffusion to smooth muscles → vasodilatation • Contraction of bronchi, intestine & large blood vessels occur via stimulation of PLC-coupled H1 receptors followed by increased IP3 & DAG

  5. Histamine Receptors & Mechanism of Action • Gastric acid secretion is via parietal cells H2 receptor stimulation by histamine from ECF cells • H2 receptor stimulation→ increased c.AMP → activation of H+/K+-ATPase (proton pump) • H3 receptors are located both in the CNS (histamine is a neurotransmitter) & in the periphery • Histamine on H3 receptors inhibits its own release (autoreceptors) as well as inhibition of release of other neurotransmitters (hetero-inhibitory effect) • H3 receptors appear to be coupled to Ca2 influx reduction through N-type Ca2+ channels

  6. Actions of Histamine • Increased vascular permeability (H1 & H2): capillary dilation & increased permeability of post-capillary venules → leakage of plasma proteins & fluids into extracellular spaces • This leads to the dermal “triple response” upon local injury: redness, wheal formation, & flare • Heart: Increased heart rate (H2) and positive inotropic effect (H1 & H2), at moderate-high dose • Sensory nerve endings stimulation leading to pain & itching

  7. Actions of Histamine • Stimulation of exocrine glands secretions: • Nasal & bronchial secretions (H1 receptors) • Gastric acid secretion (H2 receptors) • Stimulation of epinephrine secretion from adrenal medulla via stimulation of H1 receptors on chromaffin cells • Possible pathophysiologic role in migraine

  8. Histamine H1 Receptor Blockers (Antihistamines) • Ethanolamines: • Diphenhydramine, Dimenhydrinate* • Ethylenediamines: • Tripelennamine, antazoline, naphazoline • Alkylamines: • Chlorpheniramine, brompheniramine • Piperazines: Cyclizine*, meclizine*, cetrizine (2ndgeneration) • Phenothiazines: Promethazine • Piperidines: (New, Second-Generation) • Loratidine, desloratidine, fexofenadine * Mainly used for prevention of nausea, vomiting & motion sickness

  9. Antihistamines • Mechanism of Action:Competitive inhibitors for histamine at H1 receptors (structural analogs) • They antagonize all actions of histamine except for the gastric acid stimulation & H2-mediated vasodilatation • Pharmacokinetics: Well absorbed orally, max serum level in 1-2 hrs • Old first-generation agents have wide tissue distribution including CNS • Newer 2nd generation are not (non-sedative) • Duration of older members: 4-6 hrs, piperazine derivatives & 2nd generation drugs have a long duration of ≥24 hrs

  10. AntihistaminesPharmacological Actions • Inhibition of histamine-induced contraction of respiratory & GIT smooth muscles • Abolish H1-mediated vasodilatation & increased capillary permeability • Reduction of salivary, histamine-mediated bronchial & lacrimal secretions • Most antihistamines cause CNS depression, but in some patients restlessness may occur. • The antimotion sickness effect is partly mediated through the anti-cholinergic effect

  11. AntihistaminesReceptors Blocked & Adverse Actions • Receptors selectivity: 1st generation antihistamines are of poor H1 receptor selectivity. They block other receptors leading to adverse effects: • Cholinergic R blockade: dry mouth, urinary retention, & tachycardia • -adrenergic R blockade, by promethazine, leading to hypotension, tachycardia & dizziness • Serotonin R blockade leading to increased appetite

  12. AntihistaminesAdverse Actions • Sedation: 1st generation antihistamines have high CNS penetration leading to sedation • In addition, they may cause tremors, dizziness, tinnitus & fatigue • 2nd generation antihistamines have no or minor sedation and other CNS effects being more specific for H1 & poor CNS penetration • This might interfere with driving ability or to work machinery (use second generation) • Anticholinergic side effects especially dry mouth & blurred vision

  13. AntihistaminesAdverse Actions • Local anesthetic activity that can lead, at high dose level to: • CNS stimulation & convulsions, (observed in attempted suicide with antihistamines) • Cardiac depression • Drug interactions; increasing CNS sedation of other sedatives, increased activity when given with CYT P450 inhibitors (terfenadine was withdrawn) • Acute poisoning: hallucination, excitement, & convulsions (fever & flushed skin in children) • If untreated, it leads to coma & cardiorespiratory depression

  14. AntihistaminesTherapeutic Uses • Allergic Conditions • Acute allergic rhinitis (hay fever) • Acute skin reactions (urticaria, drug rashes) • NOT in bronchial asthma or chronic skin allergies • Prevention of motion sickness & CTZ/vestibular nausea: cyclizine, meclizine & dimenhydrinate are the most effective members • OTC Sedative/hypnotics for insomnia treatment: • Diphenhydramine & doxylamine have strong sedative effect

  15. Histamine H2 Receptor Blockers • No or little H1 receptor affinity • They block H2 receptors on gastric parietal cells attenuating gastric acid secretion • Main use is treatment of peptic ulcer • Agents include • Cimetidine • Ranitidine • Famotidine

  16. 5-Hydroxytryptamine (5-HT, Serotonin) • Serotonin is an amine synthesized from L-tryptophan by an hydroxylase enzyme • MAO & aldehyde de-hydrogenase degrade 5-HT into 5-hydroxyindoleacetic acid (5-HIAA) • Storage: • 90% is present in enterochromaffin cells of the GIT • Other in platelets & CNS

  17. Serotonin Receptors & Functions • Seven receptors, 5-HT1- 5-HT7 for serotonin are characterized, the first four have related functions • All types are G-protein coupled receptor except 5-HT3 receptors that are inotropic receptors

  18. Serotonin Pharmacological Actions • CNS: 5-HT plays a role in regulation of mood, food intake & sleep (5-HT1A-D) • Blood vessels: Vasodilation (5-HT1A-D) in skeletal muscles & coronaries & cerebral constriction • Vasoconstriction (5-HT2, PLC-coupled) in splanchnic, renal, pulmonary vasculature • Heart: increased heart rate & contractility (5-HT1) • Reflex cardiac slowing & hypotension via 5-HT3 receptor stimulation in coronaries & baroceptors • Stimulation of platelet aggregation

  19. 5-HT Receptor Agonists (5-HT RAs) (Triptans) • 5-HT analogues that are agonists on 5-HT1A/1D showed effectiveness against migraine • In migraine, evidence indicates the activation of the trigemino-vascular system leading to dilation & neurogenic inflammation (antidromic release of proiflammatory peptides & neuropeptides) • Mechanism: 5-HTRAs stimulate 5-HT1A/1D receptors in the intracranial vasculature & sensory nerves of the trigeminal system leading to: • Cerebral vasculature vasoconstriction • Inhibition of release of proiflammatory peptides (kinins) & neuropeptides

  20. 5-HT Receptor Agonists (5-HT RAs) (Triptans) Eletriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan • Use: Acute treatment of attacks +/-aura, not for prophylaxis • Not used in hemiplegic or opthalmogenic migraine • Not combined with ergotamine derivatives nor selective serotonin reuptake inhibitors (SSRIs) • Contraindicated with coronary artery disease, congenital heart disease, atherosclerosis, severe hypertension or seizures • Not used in patients below 18 (or <12 for Zolmitriptan) • Safety in pregnancy/lactation not tested

  21. 5-HT RAs Adverse Effects & Pharmacokinetics • Angina pectoris-like syndrome, arrhythmias, CA spasm, MI, cerebral hemorrhage, stroke & increased blood pressure in susceptible patients • Pharmacokinetics: • Mostly significant pain relief within 4 hours • Severe renal/hepatic impairment can affect their biotransformation & clearance (dose reduction) • Average oral bioavailability, sumatriptan being the lowest (14%) • Selective serotonin reuptake inhibitors (SSRIs) are used as antidepressants (Details in Depression): • Fluoxetine, paroxetine, sertaline, citalopram

  22. Other 5-HT AntagonistsErgot Alkaloids They are of fungal origin & used as oxytocic drugs, e.g., ergometrine (ergonovine) & Me-ergometrine • Ergotamine & dihydroergotamine have 5-HT1D agonist activity, in addition to -adrenergic stimulation & direct vasoconstriction • They are used in early-onset phase of migraine • Used in combination with caffeine • Adverse effects include nausea & vasoconstriction that may lead to angina or stroke • Methysergide: discussed later slide

  23. Peripheral 5-HT Antagonists • Methysergide: Both antagonist on 5-HT receptors & a partial agonist • Prophylactic migraine treatment • It takes 1-2 days for full effect, • Not used during acute attack • Chronic use should not exceed 6 months without 3-4 weeks methysergide-free period • Its frequent side effects limit its use; retro-peritoneal & pulmonary fibrosis, aortic/valular fibrosis, insomnia, alopecia • Dose should be gradually tapered off for2-3 weeks to avoid rebound headache

  24. Peripheral 5-HT Antagonists • Pizotifen, a potent 5-HT & histamine antagonist used for migraine anaphylaxis reducing the frequency & severity of attacks • Side effects include drowsiness, headache, potentiation of CNS depressants, dry mouth, impotence and hepato-toxicity (chronic use) • Cyproheptadine, a potent 5-HT & histamine antagonist used as antipruritic agent • In children, it may cause weight gain & increased growth rate

  25. Peripheral 5-HT Antagonists • Ketanserin, a 5-HT2 receptor antagonist • It causes vasodilation lowering blood pressure, and considered for hypertension treatment • It has - & H1- receptor blocking activity • Ondansetron & granisetron are 5-HT3 receptor antagonists used for prevention of nausea & vomiting caused by radiotherapy or chemotherapy • Side effects: headache, cardiac rhythm changes,

More Related